Early studies of linear yeast artificial chromosomes identified three essential elements required to ensure correct duplication and segregation of linear eu karyotic chromosomes 1 : an origin of replication 2,3 , a centromere 4, 5 , and a pair of telomeres at the extreme ends of the chromosome 6 . Human telomeres consist of a highly conserved, Grich, repetitive hexa nucleotide sequence (TTAGGG) n 7,8 , approximately 5-15 kb in length 9 . A complex of six proteins -collectively termed shelterin -is associated with the telomeric DNA repeats (telomeric repeatbinding factor 1 and 2 (TERF1 and TERF2, also known as TRF1 and TRF2), TRF2interacting protein 1 (TERF2IP, also known as RAP1), TRF1interacting nuclear factor 2 (TINF2, also known as TIN2), protection of telo meres protein 1 (POT1), and tripeptidyl peptidase 1 (TPP1)) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The linear nature of human chromo somes poses several biological dilemmas that these telomeric nucleoproteins help mitigate. The extreme ends of chromosomes are potential substrates for exo nucleolytic degradation and can also be recognized as a DNA doublestrand break by the DNA dam age response (DDR) pathway. Telomeres of suffi cient length safeguard against exonuclease activity and DDR recognition by forming specialized T-loop structures 21 and serve as a scaffold for shelterin pro teins that inhibit potentially deleterious DNA repair mechanisms at the telomeres 20 . Telomeres are integral to cellular proliferation barriers that ensure finite replicative capacity in cells, serving as a potent anticancer mechanism 22, 23 . During DNA replication, synthesis on the lag ging DNA strand of linear templates is incomplete (end replication problem) 24, 25 , resulting in the loss of ~50 terminal nucleotides in each round of cellular divi sion 26 . For a limited number of population doublings, telomeres buffer against the loss of information carrying DNA sequences. However, when telomeres become substantially shortened, the DDR pathway is activated on one or more telomeres, and cell cycle progression is arrested via the tumour suppressor p53 pathway [27] [28] [29] . 
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Abstract | Aberrations in telomere biology are among the earliest events in prostate cancer tumorigenesis and continue during tumour progression. Substantial telomere shortening occurs in prostate cancer cells and high-grade prostatic intraepithelial neoplasia. Not all mechanisms of telomere shortening are understood, but oxidative stress from local inflammation might accelerate prostatic telomere loss. Critically short telomeres can drive the accumulation of tumour-promoting genomic alterations; however, continued telomere erosion is unsustainable and must be mitigated to ensure cancer cell survival and unlimited replication potential. Prostate cancers predominantly maintain telomeres by activating telomerase, but alternative mechanisms of telomere extension can occur in metastatic disease. Telomerase activity and telomere length assessment might be useful in prostate cancer diagnosis and prognosis. Telomere shortening in normal stromal cells has been associated with prostate cancer, whereas variable telomere lengths in prostate cancer cells and telomere shortening in cancer-associated stromal cells correlated with lethal disease. Single-agent telomerase-targeted treatments for solid cancers were ineffective in clinical trials but have not been investigated in prostate cancer and might be useful in combination with established regimens. Telomere-directed strategies have not been explored as extensively. Telomere deprotection strategies have the advantage of being effective in both telomerase-dependent and telomerase-independent cancers. Disruption of androgen receptor function in prostate cancer cells results in telomere dysfunction, indicating telomeres and telomerase as potential therapeutic targets in prostate cancer.
replicative senescence and occurs after ~50 cell divi sions (the Hayflick limit), depending on cell type. Failure to block cell cycling via the p53 pathway can have devastating genomic consequences, mani fested as endtoend chromosomal fusions, anaphase bridges, nonreciprocal translocations and aneuploidy. All these processes help to promote cellular trans formation via the stochastic inactivation of tumour suppressor genes and activation of oncogenes [30] [31] [32] [33] [34] . To achieve unlimited replicative capacity, cancer cells must eventually resolve the end replication prob lem. Predominately, cancers maintain their telomeres by activating telomerase, a telomerespecific enzyme that extends telomeres 35 , therefore obviating the end replication problem. Approximately 5-10% of can cers employ a telomeraseindependent mechanism to maintain and extend telomeres called the alternative lengthening of telomeres (ALT), which is thought to rely on homologydirected DNA recombination 36, 37 . ALT is frequently observed in nonepithelial cancers, but ALT has been reported in a subset of advanced, lethal metastatic prostate tumours 38 (FIG. 1) . By con trast, ALT has not been observed in primary prostate cancers, of which the vast majority, if not all, employ telomerase for telomere maintenance 39 . In this Review, we highlight the function of tel omeres that specifically relate to prostate cancer. We describe the shorttelomeres phenotype observed in the majority of precancerous prostate lesions and prostate tumours and the potential sources of tel omere shortening in prostate cancer. Furthermore, we discuss how telomere shortening and telomerase activation result in genomic instability, consequently contributing to tumour promoting mutations. Finally, we delineate the clinical implications of telomere dys function and the therapeutic potential of treatments targeting telomerase and telomeres in patients with prostate cancer.
Role in prostate pathophysiology
Telomerase, a reverse transcriptase, extends chromosome ends with a concatemer of the telomeric TTAGGG repeat sequence 40 . The creation of the enzyme is a complex orchestration of several proteins and nucleic acids partic ipating in the biogenesis and localization of telomerase 41 . The core components for DNA extension activity consist primarily of the catalytic telomerase reverse transcriptase protein (TERT) and the telomerase RNA component (TERC, also known as hTR), which contains the repet itive telomeric sequence that functions as a template for the reverse transcriptase 42, 43 . Telomerase expression is repressed in most human somatic cells, but detectable levels of activity exist in germline and somatic stem cells 44 . Prostate cancers activate telomerase to maintain telomeres, but the telomeres in prostate cancer cells, as directly assessed in situ, are abnormally short in the vast majority of clinical samples compared with matched adjacent normal prostate tissue 39 . Southern blot ana lysis of terminal restriction fragments (TRFs) shows that the average telomere length of normal prostate tissue is 6.6 kb, whereas prostate cancer tissue has a considerably shorter average telomere length of 5.4 kb 39 . This finding is per haps not surprising, considering that even adult stem cells in epithelial tissues with activated telomerase are subject to telomere shortening over time, presumably because the amount of telomerase present is unable to fully offset the end replication problem. In the same study, the average telomere length of BPH tissue was 6.4 kb, which is comparable to that of the normal prostate. These reported telo mere lengths are probably an overestimation of the actual telomere length, as the TRF Southern blot tech nique detects not only pure TTAGGG telomeric repeats but also degenerate and variant subtelomeric sequences, resulting in estimates that are 4 kb higher than the actual telomere region consisting exclusively of telomere repeats 26, 45 . In addition, contaminating normal cells artifi cially increase measured average telomere lengths in bulk tissue analyses.
Similar to prostate cancer, prostatic intraepithelial neoplasia (PIN) and BPH are characterized by an ab normal increase in cell proliferation. Localized pros tate cancer has an ~7fold increased cell proliferation rate compared with normal prostatic epithelial tissue 46 . High-grade PIN (HGPIN) tissue proliferates ≥6fold faster than normal prostate 46 , and has abnormally short telo meres 47 . BPH tissue proliferates at a 2-3fold higher rate than normal prostate 48 but, surprisingly, does not display the telomere shortening expected to accompany abnor mally high cell proliferation in a telomerase negative setting 39 . Kinetic studies of abnormal lesions in the prostate also show that BPH tissue is indeed less proliferative than PIN tissue 49 , which might partially account for the lack of telomere shortening observed in BPH. Alternatively, the inconsistency in telomere length might be caused by a difference in the proliferative topology between BPH and HGPIN tissues 50 . Normally, proliferation in pros tatic epithelial tissues is mainly restricted to the basal cell compartment, where stem cells are thought to reside [51] [52] [53] . However, in HGPIN lesions, hyper proliferation occurs in
Key points
• Telomerase activation or the cancer-specific, telomerase-independent alternative lengthening of telomeres (ALT) mechanism are two telomere maintenance mechanisms in human cells. both basal and luminal epithelial cells 54, 55 and the majority of proliferation occurs in the luminal compartment 50, 53, 56 . Correspondingly, telomere shortening in HGPIN tissue is observed in luminal cells only and not the basal cell compartment 47 . By contrast, hyperproliferation in BPH occurs in both stromal and epithelial cells. Furthermore, proliferation of epithelial cells in BPH mainly occurs in the basal compartment 53, 56 , similar to normal prostate, which implicates stem cells and stemlike cells in the aeti ology of BPH. Consistent with this notion, a report from 2016 suggested that the telomerasenegative epi thelial cells in BPH with normal telomere length arise from telomerase positive progenitor cells that differentiated from stemlike cells residing in the basal compartment 57 . Thus, the lack of short telomeres in BPH could be caused by widespread proliferation of multiple progenitor cells, in contrast to cancer, which is traditionally thought to be the result of clonal expansion originating from a single transformed cell. HGPIN lesions share many features with prostate cancer; hence, HGPIN are believed to be the malignant precursors of prostate cancer 58, 59 , which strongly implicates telomere shortening as an early event in prostate tumorigenesis (FIG. 1) . Evidence to define a con crete timeline of telomere shortening and the transition point from HGPIN to cancer is limited, but telomerase activation is likely to be a key event. The precise timing of telomerase activation during prostate tumorigenesis is unknown. However, studies have indicated that at least a subset of HGPIN lesions have detectable telo merase 60, 61 , suggesting that considerable telomere shortening ostensibly occurs before telomerase activation in HGPIN.
Cancer is a disease of ageing, and prostate cancer is not unusual in that regard. The median age for pros tate cancer diagnosis is 67 years 62 . Prostate cancer is an exceptionally slowgrowing cancer compared with other solid tumours 63 . A clonal outgrowth of prostate cancer has been estimated to take ~40 years to reach a size of 1 cm 3 (REF. 46 ). The even lower rate of proliferation in the normal prostate is not consistent with a timeline that would result in substantial telomere shortening before transformation, and such substantial shortening is also not observed. On the basis of an estimated 500day turn over rate of the prostatic epithelium 46 , and the Hayflick limit of 50 population doublings 23, 64 , normal prostate cells would take ~68 years to reach replicative senes cence. Furthermore, prostate cells would take an addi tional 27 years of proliferation to achieve critical telomere lengths, when one or more telomeres become dysfunc tional. These estimates assume that, during tumorigen esis, prostate cells need to bypass replicative senescence, that 50 bp of telomere content are lost per division 26 , and that the difference between senescent cells and cells in crisis is 1 kb of telomere content 65 . On the basis of these conservative numbers, prostate cells would need to proliferate for almost 100 years before telomeres were sufficiently shortened to result in the telomeredriven genomic instability required for normal prostate cells to develop into precursor lesions. Taken together, the com bined observations of relatively slow proliferation rates of normal prostate cells and luminalcellspecific telomere shortening in prostate cancer and precursor HGPIN lesions suggest that additional factors (for example, oxi dative stress, perhaps from local inflammatory processes) might work in concert with cell proliferation to acceler ate the process of telomere shortening in precancerous HGPIN lesions and perhaps further in prostate cancer.
Telomeres and genomic alterations
Oxidative DNA damage and inflammation Telomeres are particularly susceptible to telomere shortening in response to DNA damage, which might be aggravated by persistent inflammation and the pro duction of reactive oxygen species (ROS) (FIG. 2) . ROS are inherent byproducts of cellular respiration, arising from multiple endogenous sources, including the electron transport chain in mitochondria 66 . However, additional endogenous and exogenous sources of free radicals can increase ROS levels above baseline with devastating cel lular consequences. A particularly wellcharacterized effect of elevated ROS levels is increased DNA damage 67 . Telomeres gradually shorten in each round of cell division owing to incomplete replication of the lagging DNA strand during DNA synthesis. To sustain unlimited replicative capacity, prostate cancer cells activate telomerase; however, they maintain short telomeres during prostate tumorigenesis and cancer progression, which can be seen in biopsy samples following fluorescence in situ hybridization staining (telomeres: red, Cy3-labelled anti-telomeric probe; basal cells: green, anti-cytokeratin antibody 34bE12; DNA: blue, DAPI). In the normal prostate, telomere lengths are relatively similar between luminal (arrows) and basal cells. However, in prostatic intraepithelial neoplasia (PIN), telomere staining in the luminal cell is substantially less than in the basal cells, indicative of telomere shortening in the luminal compartment. In prostate cancer, which lacks basal cells, the telomere staining is substantially less than in neighbouring stromal cells (asterisks). Likewise, in cancer metastases, telomere staining is less than in infiltrating lymphocytes (asterisks, reduced nucleus size). In a subset of metastatic prostate cancer cells, alternative lengthening of telomeres (ALT) mechanisms are activated, possibly as a response to treatment or environmental factors. Bright telomeric DNA foci are characteristic of ALT. 
8-Oxoguanine
The best-characterized and highly abundant DNA lesion arising from the oxidation of guanine through reactive oxygen species.
Base excision repair (BER). The DNA repair pathway that employs specialized DNA glycosylases, N-glycosylase/ DNA lyase and adenine DNA glycosylase, to repair 8-oxoguanine.
The predominant species of free radicals that contrib ute to cellular DNA damage are hydroxyl radicals (•OH) arising from superoxide radicals (•O 2 − ) and hydrogen peroxide (H 2 O 2 ) [68] [69] [70] . Guanine has the lowest oxidation potential of the DNA bases 71 . As a result, the oxidation of guanine to form 8-oxoguanine is the most abundant of the many DNA mutations that arise from ROS exposure 72 .
Telomere sequences are rich in guanine nucleotides and, consequently, telomeres are particularly susceptible to oxidative damage by ROS. Cells in culture exposed to increasing amounts of radiation have a dosedependent increase in 8oxoguanine abundance and telomere loss 73 . 8Oxoguanine DNA lesions are recognized and excised by 8oxoguanine glycosylase and the abasic site is repaired via the base excision repair (BER) pathway 74 . During BER, a singlestrand DNA break is generated following the glyco sylase step by AP endonuclease 1. BER operates during all phases of the cell cycle, including in dividing cells 75 , which is particularly relevant, as singlestrand DNA breaks in telomeres seem to accelerate the rate of telomere short ening in proliferating cells 76 . Telomeres have a higher frequency of singlestrand DNA breaks than any other part of the genome, singlestrand breaks induced by oxidative damage in telomeres accumulate and repair is substantially delayed 77 . The reduced repair efficiency in telomeres 78 might in part be explained by suppression of DNA repair by the shelterin complex to prevent telomere ends from being recognized as doublestrand breaks 79 . In addition to oxidative damage, the abundance of guanine nucleotides in telomeres also makes them susceptible to (2) . ROS can cause oxidization of guanine to form 8-oxoguanine (3), and incomplete base excision repair of 8-oxoguanine (4) can trigger DNA polymerase replication stalling and replication fork collapse at telomeres (5) . Because DNA damage response is repressed at chromosomal ends, resulting in incomplete telomere replication, telomeres are vulnerable to severe and unmitigated telomere erosion.
G-Quadruplexes
Nucleic acid secondary structures arising from Hoogsteen base pairing (an alternative form of base pairing) interactions of guanine residues.
Fragile sites
Unstable regions in the genome that are prone to break under replication stress.
Prostatic inflammatory atrophy
Prostatic lesions characterized by increased proliferation and atrophic morphology of prostatic luminal epithelial cells, associated with local inflammatory cells.
Chromothripsis
Multiple translocation events occurring in a single catastrophic event leading to imperfect rearrangement and repair of one or a few shattered chromosomes.
the formation of G-quadruplexes, which interfere with replication 80 . The helicases BLM and RTEL1 resolve Gquadruplexes at telomeres and, in cooperation with the shelterin protein TRF1, help prevent replication fork stalling to ensure efficient replication at telomeres 81 . However, these processes are not perfect and telomeres are prone to develop DNA strand breaks; thus, they behave as fragile sites in the chromosome 81 . One hypo thesis is that DNA damage, such as that caused by oxi dative stress, exacerbates the fragile site phenotype of telomeres and that incomplete replication at telomeric ends caused by replication fork stalling at persistent sites of DNA lesions promotes critical telomere shortening 82 . In addition to metabolic sources of free radicals, inflam mation can locally increase levels of ROS in tissues. ROS are generated by immune cells as part of the immune response against infection by pathogens, acting as signalling molecules, nonspecific antimicrobials, and mediators of inflammation 83 .
Inflammation is an important component in the initiation and progression of many cancers and accu mulating evidence supports a similar role in prostate cancer [84] [85] [86] . The presence of inflammation, mostly chronic, in benign prostate biopsy tissues was found to be associated with prostate cancer, particularly high grade disease 87 . Furthermore, use of antiinflammatory medications, specifically acetylsalicylic acid and other nonsteroidal antiinflammatory drugs, is associated with reduced risk of developing prostate cancer 88 . Prostatic inflammation is common 86, [89] [90] [91] [92] [93] and inflammatory trig gers include infectious agents (for example, bacteria and viruses), dietary factors, oestrogen exposure, physical trauma from corpora amylacea, and the physical and chemical irritation from urine reflux 85, 94, 95 . The histological sequelae, presumably caused by acute and/or chronic inflammation in the prostate, include prostatic inflammatory atrophy (PIA) 85 . These morphologically atrophic lesions are characterized by an increased proliferation of epithelial cells (to a mean proliferation rate of 10.7fold above normal epithelial cells) [96] [97] [98] and the presence of activated inflammatory cells (predominately lymphocytes and macrophages) 96, 99 . These proliferation rates would lead epithelial cells in PIA lesions to have increased telomere shortening and, therefore, to reach replicative senescence considerably faster than normal prostate cells. Thus, PIA has been sug gested to be a precursor to PIN and subsequent prostate cancer 85 . Intriguingly, PIA lesions tend to histo logically merge into HGPIN in the prostate 100 , supporting the notion that PIA is a precursor to PIN. In addition, the relative frequency of prostatic inflammation is similar to the demographic frequency of prostate cancer in men. For example, American men of African origin are at increased risk of developing prostate cancer 101 and have increased rates of prostatic inflammation compared with American men of European decent 102 . One interesting observation of prostate cancer epidemiological data is that American men with parents who have migrated from Asia have substantially increased rates of prostate cancer compared with Asian men who did not migrate, strongly implicating an environmental component 103 .
Switching from an Asian, possibly antiinflammatory diet including tea and soy products to a Western, pro inflammatory diet has been suggested as a contributing factor to the increased prevalence of prostate cancer observed in men of Asian descent 104 . Taken together, the link between telomere shorten ing and prostate cancer might, in part, be explained by connecting telomere shortening to oxidative stress: the generation of ROS owing to inflammation, the prepon derance of inflammation in the prostate, and the asso ciation between prostatic inflammation and prostate cancer, potentially driven largely by environmental fac tors, such as microorganisms or diet. As a precursor to PIN and subsequently prostate cancer, an inflammatory environment potentially drives PIA towards malignant transformation.
Interestingly, in addition to PIN and prostate cancer cells, telomere shortening has also been observed in normal stromal cells and is associated with increased prostate cancer risk 105 . The specific stromal cell types that have short telomeres have yet to be identified, but the telomere shortening in these stromal cells might be a direct result of inflammation.
Inflammation also seems to have a role in the devel opment of BPH 106 , but BPH does not display substantial telomere shortening in contrast to HGPIN and pros tate cancer 39, 47 . Presumably, the telomerase activity in the postulated epithelial progenitor cells and stemlike cells in BPH would not safeguard against genomic insults from ROS. However, glutathione Stransferase P (GSTP), which is expressed in normal prostate and BPH but not in HGPIN or prostate cancer 107, 108 , does have activity against reactive oxidants and electro philes that could damage DNA 109, 110 . Perhaps, BPH is not susceptible to telomere shortening from hyper proliferation and oxidative DNA damage because of the maintenance activity of telomerase in postulated epithelial progenitor cells and stemlike cells 57 and the detoxification activity of GSTP 50 , respectively. By contrast, the short telomeres in HGPIN should result in considerable selective pressure for halting telomere loss. During tumorigenesis, critically short telomeres can precipitate many important cancer promoting mutations, such as telomerase activation, by encouraging global genomic instability.
Genomic alterations due to short telomeres
Telomere shortening is one of the earliest molecular genomic events in prostate tumorigenesis and can generate genomic instability. Genomic translocation events are prevalent in prostate cancer and were tradi tionally thought to accumulate gradually during tum origenesis. However, chromothripsis can occur, in which multiple translocation events occur in a single cata strophic event leading to imperfect rearrangement and repair of one or a few shattered chromosomes [111] [112] [113] . Mutations in the genome resulting from chromothrip sis can be involved in tumour initiation or progression through the generation of fusion genes, inactivation of tumour suppressors, and amplification of onco genes [114] [115] [116] [117] . Cell culture experiments with artificially shortened telomeres have demonstrated that critically short telomeres can precipitate chromothripsis 118 . Approximately 30-45% of prostate cancers show DNA rearrangements resembling the translocation events typified by chromothripsis 119 . Chromothripsis notwithstanding, early contribu tions of telomere shortening to genomic instability are evident in the form of telomere fusions, which have been reported to occur in >50% of assessed prostate cancer precursor lesions derived from radical prosta tectomy specimens 120 . These chromosomal endtoend fusions of dysfunctional short telomeres can elicit the canonical breakagefusionbridge (BFB) cycles, in which missegregation of fused chromosomes during mitosis perpetuates a cycle of fused chromosomes improperly breaking and fusing in an errorprone manner 31 . BFB cycles result in substantial chromo somal rearrangements, particularly duplications and deletions, and nonreciprocal trans locations 121 . Studies in wellcharacterized prostate cancer cell lines have shown that short telomeres can drive the complex chromosomal rearrangements characteristic of pros tate cancer through BFB cycles, despite telomerase activation 122 .
Telomerase activation in prostate cancer
Most cancer cells activate the enzyme telomerase for telomere maintenance to support unlimited replicative capacity and to prevent an intolerable level of genomic instability. In human cancers, the ratelimiting determi nant for telomerase activity is thought to be expression of the catalytic protein subunit TERT. Telomerasepositive cultured human cells contain ~1,150 TERC mole cules and ~500 TERT molecules per cell 123 . However, estimates of the number of functional, assembled tel omerase complexes range from 20 to 240 complexes per cell 123, 124 , suggesting an excess of unassembled com ponents of telomerase 123 . The transcription of TERT is tightly regulated and experimental evidence indicates that telomerase activity directly corresponds with TERT expression 125, 126 . Furthermore, in somatic cells, forced expression of TERT is sufficient to reactivate telomerase activity [127] [128] [129] .
The androgen receptor (AR) is essential for stimu lating the expression of genes important for the male phenotype, including the development, maintenance, and function of the prostate 130 . The first in vivo study of telomerase activity in the prostate of rats showed that normal prostate glands lacked telomerase activity, but involuted prostate glands, following androgen depriva tion via castration, had detectable levels of telomerase activity 131 . Reintroduction of androgen in castrated rats stimulated regrowth of the prostate and phenocopy of the precastration prostate in which no telomerase was detected, suggesting that androgen negatively regulates telomerase activity 131 . Similar observations were later made in rhesus monkeys 132 . In normal human prostate epithelial cells, the AR binds to the TERT promoter and, in co operation with the tumour suppressor p53, directly represses TERT expression 133 . By contrast, androgen activates TERT expression in the human prostate cancer cell line LNCaP, which has a point mutation in the AR gene that is also recurrently observed in prostate can cer 133, 134 . Treatment of prostate cancer lines with meth aneseleninic acid, which decreases AR protein levels 135 , resulted in a concomitant decrease in TERT expres sion in both ARwildtype (LAPC4) and ARmutated (CWR22Rv1, LNCaP, and LNCaP sublines) cell lines, but not in an ARnegative (DU145) cell line 136 . The decreased TERT expression in the ARpositive cell lines was reported to be a consequence of reduced AR occupancy at the TERT promoter.
Cancer cells can activate telomerase activity through upregulation of TERT expression in several ways (TABLE 1) . Two welldocumented mechanisms are hypermethylation of the TERT promoter, which has been reported in multiple cancer cell lines 137 , and acti vating point mutations in the TERT promoter, which have been observed in cancers of the central nervous system, bladder, thyroid, and skin 138, 139 . The methylation status of the TERT promoter in prostate cancer has yet to be fully investigated; however, TERT promoter muta tions have not been observed in prostate cancer 138, 140 . Instead, the MYC oncogene has been implicated as a contributor to TERT overexpression in prostate cancer. TERT amplification Amplification of TERT has not been observed in prostate cancer, but has been reported in embryonal tumours of the central nervous system, cervical carcinoma, lung adenocarcinoma, and hepatocellular carcinoma.
196-199
TERT translocation Genomic rearrangements of TERT have not been reported in prostate cancer, but have been tightly linked to high-risk neuroblastoma.
200,201
TERT promoter hypermethylation The methylation status of the TERT promoter in prostate cancer has yet to be fully investigated, but promoter methylation has been reported to occur in multiple cancer cell lines and in some cancers.
137,202
TERT promoter activating mutations TERT promoter mutations have not been observed in prostate cancer, but have been frequently observed in cancers of the central nervous system, bladder, thyroid, and skin.
138,139
MYC activation MYC positively regulates TERT expression and MYC activation coincides with the earliest detectable appearance of abnormally short telomeres during prostate tumorigenesis. >80% of prostate cancers have nuclear overexpression of MYC. Thus, MYC activation is likely to be a mechanism of TERT activation in a high proportion of prostate cancers. Increased levels of MYC are one of the earliest somatic molecular alterations observed in prostate can cer precursor lesions. In histologically normal prostatic tissues, MYC expression is localized to the basal com partment. By contrast, in PIA and both lowgrade and highgrade PIN, MYC expression abnormally localizes to the luminal compartment 141 . The precise molecular mechanisms underlying MYC activation in prostate cancer precursor lesions are not well understood. Gain of chromosome 8q, which includes MYC, is common in PIN, primary and metastatic prostate cancer, and specific amplification of the MYC locus is frequently observed in aggressive disease 150, 151 . However, amplifi cation of MYC as the cause for increased MYC protein levels in PIN is controversial 152 .
141,203

Clinical relevance
Telomere dysfunction might be a useful target for improved management of patients with prostate cancer (FIG. 3) . Potential applications that are directed at telo meres and telomerase could facilitate disease diagno sis and patient prognosis. In addition, treatments that directly target telomerase or depend on its function, as well as agents that exploit shortened telomeres and disrupted DDR, could have clinical utility in the future.
Diagnosis and prognosis of prostate cancer
Early detection is paramount to ensure the best outcomes for men diagnosed with prostate cancer, but currently available screening methods can result in overdiagnosis and overtreatment 153, 154 . Detection of telomerase activa tion could potentially aid in prostate cancer screening, owing to its high cancer specificity. The primary obsta cle to telomerase detection is the low abundance of the enzyme. Telomerasepositive human cancer cell lines contain 20-240 functional telomerase complexes per cell 123, 124 . The earliest telomerase activity assays required the use of radiolabeled nucleotides to compensate for the relatively low abundance of the protein 155 . To improve assay sensitivity, a PCRamplificationbased approach termed the telomere repeat amplification protocol (TRAP) assay was developed and used successfully to detect telomerase in prostate biopsy samples 156 . In the TRAP assay, telomerase activity is detected by addition of a synthetic telomere end to a cell or tissue lysate. If telomerase is present, the enzyme will recognize and extend the synthetic substrate, and telomerase extension products can be detected by PCR amplification.
Currently, no telomerase assays for cancer detection are clinically validated. However, considerable effort has been made to incorporate technological advances in sig nal amplification, nanotechnology, and optical detection to improve the reliability and sensitivity of the TRAP assay 157 . The detection of circulating tumour cells (CTCs) in the blood is a noninvasive procedure that has poten tial utility in the clinic. Telomerase activity measure ments could identify CTCs isolated from the blood of patients with prostate cancer. An ELISAbased TRAP assay was able to identify CTCs in 79% of patients with localized prostate cancer and in 0% of healthy men with no evi dence of prostate cancer 158 . A subsequent study using a different version of the TRAP assay demonstrated sensi tive and reliable detection of prostate cancer cells in blood collected on a microfilter platform 159 . Further studies evaluated the utility of telomerase detection in live CTCs as a prognostic tool for overall survival in patients with advanced castrationresistant prostate cancer. In a subset of patients with a baseline count of ≥5 CTCs per 7.5 ml of blood, increased telomerase activity was associated with worse outcomes 160 . Alternatively, telomere length can potentially aid in prostate cancer diagnosis. A study using quantitative telomere specific fluorescence in situ hybridization (FISH) in biopsy samples from men participating in the pla cebo arm of the Prostate Cancer Prevention Trial showed that telo mere shortening in normal stromal cells was associated with an increased prostate cancer risk 161 . At the diagnostic stage, detection of telomerase expression and measurement of telomere length might be useful, as telomerase activation and shortened telomeres are strongly associated with prostate cancer. At the prognostic level, determining telomere lengths might enable distinguishing men who will develop lethal metastatic disease from men whose disease is unlikely to advance beyond an organ-confined stage. At the therapeutic level, strategies targeting telomerase or telomeres might have clinical utility, particularly in combination with traditional prostate cancer therapies that target the androgen signalling pathway.
Peptide vaccine
A peptide conjugated with a vaccine adjuvant to stimulate an immune response against a target antigen that shares the same amino acid sequence of the peptide.
The findings of these studies need to be validated, but telomere length assessment in the stroma might be par ticularly useful in men with a negative biopsy but con tinued suspicion for prostate cancer (for example, owing to persistently elevated PSA levels) 161 . Once prostate cancer has been definitively diag nosed, the currently available prognostic tools cannot reliably predict whether a man with organconfined disease will or will not eventually develop lethal met astatic disease, particularly in patients with inter mediate pathological grade. As a result, many men undergoing treatment are thought to have cancers that would not substantially progress within their lifetimes and could, therefore, forego treatment. The potential harm from the overtreatment of prostate cancer is considerable 162 and new ways to identify the subset of men who will most probably benefit from aggressive treatment need to be identified. Telomere length measurements in biopsy samples could pos sibly augment current approaches to better inform clinicians and patients whether active surveillance or definitive treatment is more appropriate. In a prospec tive study using quantitative telomerespecific FISH to assess telomere length, the combination of more variable telomere length in prostate cancer cells and shorter telomere length in cancerassociated stro mal cells correlated with progression to metastasis and diseasespecific death, independently of existing clinicopathological indicators 105 . These findings indi cate a translational potential of tissuebased telomere measurements for prognostication that might inform risk stratification for personalized therapeutic and surveillance strategies.
Telomerase-targeted therapies
Approximately 90% of cancers activate telomerase for telomere maintenance and to achieve unlimited replicative capacity 35, 163 . Telomerase is an attractive target for anticancer therapy for two reasons. Firstly, unless cells acquire the ability to maintain telomeres in a telomerase independent fashion, the lack of telo merase will impair the cancer cell's ability for unlimited replicative capacity. Secondly, telomerase activation distinguishes normal somatic cells from cancer cells, and normal somatic cells, which lack telomerase, will not be affected by telomerasetargeted therapies.
However, targeting telomerase is not without cave ats. Germ cells and some stem or progenitor cells in highly proliferative tissues rely on telomerase to maintain their telomeres; thus, their telomere lengths would be potentially affected by telomerase inhibi tion causing adverse effects 164 . However, such possible offtarget effects were predicted to be minimal, partly owing to the large differential in telomere lengths in cancer versus normal cells. Preclinical studies showed favourable tolerance to telomeraseactive agents. As a result, telomerasedirected agents, such as imetel stat and GV1001, have advanced to clinical trials. Disappointingly, these treatments have shown no sur vival benefit, but investigation of their clinical potential has not been entirely abandoned 165 (TABLE 2) .
Imetelstat is a lipidconjugated 13mer oligonucle otide that functions as a small molecular inhibitor by binding to the RNA template TERC to disrupt telo merase activity. Several, both completed and ongoing, clinical trials have evaluated imetelstat 166 . In patients with nonsmallcell lung cancer, imetelstat did not improve progressionfree survival; however, tumours with the shortest telomeres responded to treatment better than tumours with longer telomeres, provid ing support for targetspecific efficacy 167 . One notable observation made in a failed phase II trial of imetelstat was a decrease in platelet levels in patients with breast and lung cancer following treatment with this agent 165 . In a small study, imetelstat was found to be particu larly efficacious in patients with thrombocythaemia, a hyperproliferative blood disorder characterized by overproduction of platelets by megakaryocytes 168 . Notably, the mechanism of action of imetelstat in patients with thrombocythaemia is unclear, as telomere length was not associated with clinical response 168 . The failure to establish telomerasetargeted treat ments for cancer therapy might partly be explained by the fact that telomerase inhibition does not immediately kill cancer cells and is only efficacious when telomeres become critically short. Consequently, the benefits of telomerase inhibition depend on treatment duration, proliferation rate, and initial telomere lengths 169 . Thus, telomerase inhibition might be more effective in highly proliferative cancers or cancers with exceptionally short telomeres. Although prostate cancer is typically a rel atively slow growing cancer, the telomeres are mostly substantially shortened. Thus, telomerase inhibition might have clinical utility. Studies in prostate cancer cell lines show that imetelstat causes considerable telomere shortening in the key subset of tumourinitiating cells 170 . Oncolytic virus strategies targeting telomerase expressing cells are also currently being investigated in clinical trials. Telomelysin is a replicationselective adenovirus in which expression of the viral E1 genes, which are essential for viral replication, are under the control of the TERT promoter. The oncolytic virus rep licates selectively in cancer cells that express telomerase and not in normal cells lacking telomerase, resulting in selective killing of cancer cells 171 . Completed phase I trials of telomelysin have indicated no severe adverse effects following administration; however, tumour responses in patients have been limited to date 172 . As telomerasetargeted therapies might not be effective as single agents, clinical trials are underway that investigate combination approaches. One study investigating the combination of the telomerase peptide vaccine GV1001 with gemcitabine and capecitabine did not show enhanced efficacy in patients with pan creatic cancer 173 . GV1001 is a 16mer peptide containing a TERT amino acid sequence. In this study, the peptide was combined with granulocyte-macrophage colony stimulating factor as an adjuvant 173 . Combination of GV1001 with gemcitabine and capecitabine treatment, which is the standard of care for patients with pan creatic cancer, was thought to potentially enhance the immune response generated by GV1001 vaccination.
Epithelial-mesenchymal transition
The biological process in which epithelial cells acquire characteristics more consistent with mesenchymal cells, including loss of cell polarity and adhesion, and enhanced migration and invasiveness.
The most synergistic combination therapy and optimal delivery method for telomerase inhibition might still have to be identified 165 . In prostate cancer, a potentially efficacious combination therapy inhibits both telomerase activity and AR activity. Wildtype AR in conjunction with p53 represses TERT expres sion in the prostate 133 . However, in prostate cancer, AR signalling acts in an opposite manner and upreg ulates the expression of TERT 133, 135 . Conceivably, this reversal of ARmediated TERT repression is a consequence of abrogated p53 and AR function. Metastatic castrationresistant prostate cancer is con siderably enriched in TP53 and AR alterations com pared with organconfined tumours 174 , and increased AR function in the advanced disease setting poten tially upregulates telomerase activity. Traditionally, telomerase targeted treatments have largely focused on the telomere maintenance functions of telomerase; however, compelling evidence suggests additional contributions of TERT in cancerrelevant phenotypes independent of telomere maintenance 175 , including the promotion of cell proliferation [176] [177] [178] [179] , drug resist ance 180 , and epithelial-mesenchymal transition 181 . In the clinic, prostate cancer responds to antiandrogen treat ments, albeit temporarily 182 . Targeting two essential pathways, AR signalling and telomerase, in prostate cancer simultaneously might be a promising strategy to kill tumour cells early and prevent the progression to metastatic disease. The potential synergy of com bining ARtargeted and telomerasetargeted therapies warrants preclinical studies.
Therapies directed at shortened telomeres
Therapeutic approaches directed at telomeres have not advanced as far as those targeting telomerase, but warrant further investigation (TABLE 2) . A limitation of telomerase targeted therapies is the potential for can cers to develop resistance via telomeraseindependent mechanisms, such as ALT, to maintain telomeres. Only ~10% of all cancers show de novo ALT mechanisms 35, 163 and no primary prostate cancers exhibit ALT. However, under selective pressure through, for example, telo merase inhibition, telomerasepositive cancers can adopt a telomerase independent programme of telomere maintenance 183 . When chromosomal ends are not properly pro tected, numerous proteins associated with the DDR are recruited to the site of telomere dysfunction 20 . In the DDR pathway, sites of DNA lesions, thought to be doublestrand breaks, accumulate proteins and modifi cations to signal for repair. Histone H2AX is phospho rylated at Ser139 (γH2AX) by the kinases ATM, ATR or DNAPK at the site of the DNA lesion. DNA damage signalling markers such as 53BP1, MDC1, and phospho rylated ATM aggregate at sites of γH2AX to form canon ical DNA damage foci 184 . Cancers that employ ALT 
Telomere deprotection
Telomeres partially or completely unprotected by shelterin proteins, resulting in the activation of DDR.
mechanisms to maintain their telomeres are character ized by a higher level of telomeric DDR compared with telo merase positive cells 185, 186 . One study showed that a small molecule inhibitor of ATR (VE821) was effective against ALTpositive osteosarcoma and glioma cells 187 . These findings are encouraging for therapy of ALT positive cancers, but focusing therapeutic efforts on telo meres might require a more comprehensive approach, as targeting telomeres might be efficacious in cancer regardless of telomerase dependency. To develop treat ments with maximum therapeutic index, identifying exploitable differences between telomeres in tumours and those in normal cells will be a crucial objective.
Studies in a derivative of the human IMR90 fibroblast cell line that expresses HPV16 E6 and E7 proteins, which inhibit tumour suppressors p53 and retinoblastoma protein, demonstrated that telomere fusion between chromosomes causes mitotic arrest 188 . Telomere deprotection that arose as a result of prolonged mitotic arrest acted as a molecular signal to trigger cell death. Thus, telomere deprotection might sensitize cancer cells to antimitotic drugs 189 . Intriguingly, a sub population of prostate tumour cells with elevated tel omerase activity and TERT expression were sensitive to strategies inducing apoptosis through telomere depro tection 190 . Expression of mutated TERC in these cells reprogrammed telomerase to extend telomeres with an incorrect sequence, effectively inducing telomere depro tection. Therapeutic strategies that promote telomere deprotection, such as Gquadruplex stabilizers 191, 192 , might have clinical utility in prostate cancer, particu larly in the setting of metastatic castration resistant disease, in which p53 inactivation is common 174 . Disruption of AR function in ARpositive pros tate cancer cells results in telomere dysfunction, and activates the DDR proteins ATM and check point kinase 2 (REF. 193 ). Mutational studies of the shelterin protein TIN2 showed that deletions in the Cterminal or Nterminal regions of TIN2 triggered cell death in the ARnegative and p53deficient PPC1 prostate cancer cell line but not in the ARpositive and p53positive LNCaP prostate cancer cell line, suggesting that the telomere complex might be dif ferent between ARnegative and ARpositive pros tate cancer 194 . Consistent with this notion, treating ARpositive LNCaP cells with the AR antagonists bicalutamide or enzalutamide resulted in γH2AX enrichment and recruitment of 53BP1 at telomeres. However, telomere dysfunction was not observed following bicalutamide treatment in the ARnegative PC3 cell line 188 . Furthermore, AR inactivation by knockdown, androgen deprivation, or treatment with bicalutamide in LNCaP cells induced telomere breaks and sister chromatid telomere fusion 195 . Blocking the repair of these telomere DNA lesions with an ATM inhibitor enhanced cell killing by bicalutamide in both LNCaP (androgenresponsive) and CWR 22Rv1 cells (androgeninsensitive). In this setting, ATM inhibition blocked cell cycle checkpoint arrest, pre venting the repair of damaged telomeres caused by AR inhibition, and as a result promoted cell death 193 .
These studies suggest that combination treatments including an ATM inhibitor that potentiates the effects of existing androgen deprivation therapies are effective via telomeredirected mechanisms and might have clinical utility in both androgensensitive and androgen insensitive prostate cancer.
Conclusions
Telomeres and telomerase seem to be integral to the initiation and progression of prostate cancer and, there fore, might also be relevant in the diagnosis, prognosis, and treatment of the disease (FIG. 3) . At the earliest stages of prostate tumorigenesis, telomere shortening can be observed in the precursor lesion HGPIN. The exact causes of telomere shortening in the prostate are not yet well defined, but evidence suggests an inflammatory contribution that increases local ROS production, which accelerates telomere shortening in addition to the losses caused by cell proliferation.
Critically shortened telomeres compromise genomic integrity and can drive somatic copy number altera tions, aneuploidy, and DNA rearrangements that are typically observed in the genomic landscape of pros tate cancer. The ensuing genomic instability contrib utes to the somatic molecular alterations to sustain the unlimited replicative capacity in cancer. Essential to this process is the activation of telomerase or the adoption of telo meraseindependent mechanisms to maintain telo meres. For the majority of prostate cancers, MYC is believed to be the main driver for telomerase activation.
The combination of short telomeres and telo merase activation in prostate cancer make telomerase an attractive therapeutic target. However, in clinical trials, telomerasetargeted therapies for other solid cancers have mostly proven to be ineffective as single agents. Clinical studies have not fully investigated the use of these treatments in prostate cancer, but the outcomes of singleagent treatment will probably be similarly disappointing. The utility of telomerasetargeted ther apies in prostate cancer possibly exists in combination with other established treatment regimens, such as AR inhibitors or radiotherapy. In addition, a subset of lethal metastatic prostate cancer has been shown to employ the telomeraseindependent telomere maintenance pro gramme ALT for telomere maintenance. The potential for prostate cancer to employ ALT is particularly sali ent, as this mechanism is a way for advanced prostate cancer to circumvent telomerasedirected therapies and continue to maintain and extend telomeres. Thus, inhibiting telomerase activity might not be sufficient to treat advanced prostate cancer, as ALT mechanisms might become engaged to maintain telomeres and sup port continued cell division. New findings that connect telo mere dysfunction and AR inhibition in prostate cancer cells are provocative, and reemphasize the importance of the telomeres as a potential therapeutic target in prostate cancer. Telomeredirected therapies in combination with AR inhibition, perhaps also includ ing targeting of the DDR, might have the potential to be effective in both telomeraseexpressing and ALTpositive prostate cancers.
